Boehringer Ingelheim To Boost Cancer Immunology Portfolio with Novel Cancer Vaccines

 
• By Sten Stovall

By buying AMAL, Boehringer Ingelheim plans to develop new therapies by combining assets from its cancer immunology portfolio with the biotech’s KISIMA immunization platform, the German pharma’s head of cancer immunology business development tells Scrip.

Vial
AMAL’s KISIMA platform leverages peptide/protein-based vaccination technology • Source: Shutterstock

More from Deals

More from Business